BACKGROUND/AIM: Targeted therapy has become increasingly important in treating lung adenocarcinoma, the most common subtype of lung cancer. Next-generation sequencing (NGS) enables precise identification of specific genetic alterations in individual tumor tissues, thereby guiding targeted therapy selection. This study aimed to analyze mutations present in adenocarcinoma tissues using NGS, assess the benefit of targeted therapy and evaluate the progress in availability of targeted therapies over last five years. PATIENTS AND METHODS: The study included 237 lung adenocarcinoma patients treated between 2018-2020. The Archer FusionPlex CTL panel was used for NGS analysis. RESULTS: Gene variants covered by the panel were detected in 57% patients and fusion genes in 5.9% patients. At the time of the study, 34 patients (14.3% of patients) were identified with a targetable variant. Twenty-five patients with EGFR variants, 8 patients with EML4-ALK fusion and one patient with CD74-ROS1 fusion received targeted therapy. Prognosis of patients at advanced stages with EGFR variants treated by tyrosine kinase inhibitors and patients with EML4-ALK fusion treated by alectinib was significantly favorable compared to patients without any targetable variant treated by chemotherapy (p=0.0172, p=0.0096, respectively). Based on treatment guidelines applicable in May 2023, the number of patients who could profit from targeted therapy would be 64 (27.0% of patients), this is an increase by 88% in comparison to recommendations valid in 2018-2020. CONCLUSION: As lung adenocarcinoma patients significantly benefit from targeted therapy, the assessment of mutational profiles using NGS could become a crucial approach in the routine management of oncological patients.

Biomedical Center Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Biopticka laboratory s r o Pilsen Czech Republic

Department of Biology Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Department of Biology Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic;

Department of Histology and Embryology Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Department of Immunochemical Diagnostics University Hospital Pilsen Pilsen Czech Republic

Department of Medical Chemistry and Biochemistry Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Department of Pneumology and Phthisiology Faculty of Medicine in Pilsen University Hospital Pilsen Charles University Pilsen Czech Republic

Department of Surgery University Hospital Pilsen Pilsen Czech Republic

Sikl's Department of Pathology University Hospital Pilsen Pilsen Czech Republic

Zobrazit více v PubMed

Siegel R, Miller K, Fuchs H, Jemal A. Cancer statistics, 2022. CA: CA Cancer J Clin. 2022;72(1):7–33. doi: 10.3322/caac.21708. PubMed DOI

Zappa C, Mousa S. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288–300. doi: 10.21037/tlcr.2016.06.07. PubMed DOI PMC

Hirsch F, Scagliotti G, Mulshine J, Kwon R, Curran W, Wu Y, Paz-Ares L. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299–311. doi: 10.1016/S0140-6736(16)30958-8. PubMed DOI

Pesta M, Shetti D, Kulda V, Knizkova T, Houfkova K, Sharif Bagheri M, Svaton M, Polivka J. Applications of liquid biopsies in non-small-cell lung cancer. Diagnostics. 2022;12(8):1799. doi: 10.3390/diagnostics12081799. PubMed DOI PMC

Planchard D, Popat S, Kerr K, Novello S, Smit E, Faivre-Finn C, Mok T, Reck M, Van Schil P, Hellmann M, Peters S. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv192–iv237. doi: 10.1093/annonc/mdy275. PubMed DOI

Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D’Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens MA, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15:504–535. doi: 10.6004/jnccn.2017.0050. PubMed DOI

Herbst R, Tsuboi M, John T, Grohé C, Majem M, Goldman J, Kim S, Marmol D, Rukazenkov Y, Wu Y. Osimertinib as adjuvant therapy in patients (pts) with stage IB-IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA. J Clin Oncol. 2020;38(18_suppl):LBA5–LBA5. doi: 10.1200/JCO.2020.38.18_suppl.LBA5. DOI

Vyzula R. Brno, Masaryk Memorial Cancer Institute. 2018. Modrá kniha České onkologické společnosti.

Kiss I. Brno, Masaryk Memorial Cancer Institute. 2022. Modrá kniha České onkologické společnosti.

Rosenberg S, Restifo N. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62–68. doi: 10.1126/science.aaa4967. PubMed DOI PMC

Vokes N, Pan K, Le X. Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer. Ther Adv Med Oncol. 2023;15:175883592311614. doi: 10.1177/17588359231161409. PubMed DOI PMC

Zheng Y, Vioix H, Liu F, Singh B, Sharma S, Sharda D. Diagnostic and economic value of biomarker testing for targetable mutations in non-small-cell lung cancer: a literature review. Future Oncol. 2022;18(4):505–518. doi: 10.2217/fon-2021-1040. PubMed DOI

Xiao Y, Liu P, Wei J, Zhang X, Guo J, Lin Y. Recent progress in targeted therapy for non-small cell lung cancer. Front Pharmacol. 2023;14:1125547. doi: 10.3389/fphar.2023.1125547. PubMed DOI PMC

Yun J, Nakagawa R, Tham K. KRAS-targeted therapy in the treatment of non-small cell lung cancer. J Oncol Pharm Pract. 2023;29(2):422–430. doi: 10.1177/10781552221118848. PubMed DOI

Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci. 2002;99(19):12293–12297. doi: 10.1073/pnas.192461099. PubMed DOI PMC

Willard N, Sholl L, Aisner D. Panel sequencing for targeted therapy selection in solid tumors. Clin Lab Med. 2022;42(3):309–323. doi: 10.1016/j.cll.2022.04.004. PubMed DOI

Pellini B, Szymanski J, Chin R, Jones P, Chaudhuri A. Liquid biopsies using circulating tumor DNA in non-small cell lung cancer. Thorac Surg Clin. 2020;30(2):165–177. doi: 10.1016/j.thorsurg.2020.01.005. PubMed DOI

Claerhout S, Lehnert S, Vander Borght S, Spans L, Dooms C, Wauters E, Vansteenkiste J, Weynand B, Deraedt K, Bourgain C, Vanden Bempt I. Targeted RNA sequencing for upfront analysis of actionable driver alterations in non-small cell lung cancer. Lung Cancer. 2022;166:242–249. doi: 10.1016/j.lungcan.2022.02.013. PubMed DOI

Kim J, Yoon S, Lee D, Jang S, Chun S, Kim S. Real‐world utility of next‐generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma. Cancer Med. 2021;10(10):3197–3204. doi: 10.1002/cam4.3874. PubMed DOI PMC

Cascetta P, Marinello A, Lazzari C, Gregorc V, Planchard D, Bianco R, Normanno N, Morabito A. KRAS in NSCLC: State of the art and future perspectives. Cancers. 2022;14(21):5430. doi: 10.3390/cancers14215430. PubMed DOI PMC

Hofmann M, Gerlach D, Misale S, Petronczki M, Kraut N. Expanding the reach of precision oncology by drugging all KRAS mutants. Cancer Discov. 2022;12(4):924–937. doi: 10.1158/2159-8290.CD-21-1331. PubMed DOI PMC